Intera Atlas
Run match
Sites / Chicago Research Center
Is this you?

Request access for Chicago Research Center with your @imaresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Chicago Research Center

Unclaimed profile

Single Site (Subsidiary of IMA Clinical Research SMO) · Chicago, Illinois · ~1 sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 3Lift (cardio sample) 0.22Recruit soph 0
Quality Scorecard (1–100)
Overall71Recruit37Ops83Sponsor87Ther85

Performance (observed)

Historical trials
389
Completed
228
Terminated/Withdrawn
44
Completion rate
84%
Active now
104
Phase 2
145
Phase 3
152
Realized enrollment
177,683
First study year
1994
Years active
32
Match confidence
high
Enrollment velocity (inf)
5,553

Therapeutic

Areas
CNS (Central Nervous System), Sleep Disorders, Psychiatry, Psychedelics, Vaccines, General Medicine
Breadth (conditions)
721
States
IL

Recruitment (web observed)

Capability notes
Large patient database (50,000+); specialized sleep lab recruitment; community-based patient access

Relationships

Sponsors
National Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; Children's Oncology Group; AbbVie; SWOG Cancer Research Network; Pfizer
CROs
Clinipace Worldwide; Croma-Pharma GmbH; ICON Clinical Research; International Partnership for Microbicides, Inc.; MacroGenics; Parexel
Owner / parent
Acquired by IMA Group (PE-backed) October 2025; operates as part of IMA Clinical Research national network (77 employees, 15+ full-service sites, 180+ satellite sites, 400K+ patient database)

Capacity & people

Investigators
—
Coordinators
—
CEO
Stacy Malm, MS, LCPC (President & CEO)
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown

Tech & DCT

Builds tech
Vendors
Tech stack
Sleep lab facility (6-bed clinical research unit); standard research infrastructure
Recruiting visible
Y

Notes

Single research site, not a multi-site network operator. Narrow therapeutic specialization (CNS/sleep focus). Founded 2005, independent until Oct 2025 acquisition by IMA Group. Now a satellite of larger PE-backed SMO. Poor ICP fit as standalone: single location, specialized (not broad) indication focus, no independent patient recruitment marketing, limited innovation. Better fit if evaluated as part of parent IMA Clinical Research network. [Validated: 21 active recruiting cardiometabolic trials on ClinicalTrials.gov.]

Recommendation features (sample indication)

Ind fit 0.22Liftability 0.22Overall71

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.